Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer
Jody V. Vykoukal, Timothy C. Thompson(The University of Texas MD Anderson Cancer Center), Adriana Paulucci-Holthauzen(The University of Texas Medical Branch at Galveston), Spyridon P. Basourakos(The University of Texas MD Anderson Cancer Center), Justin R. Gregg(The University of Texas MD Anderson Cancer Center), Jeri Kim(The University of Texas MD Anderson Cancer Center), Samir Hanash(The University of Texas MD Anderson Cancer Center), Chad J. Creighton(Baylor College of Medicine), Eunice Murage, Jeffrey Mayo(The University of Texas MD Anderson Cancer Center), Johannes F. Fahrmann(The University of Texas MD Anderson Cancer Center), Guang Yang(Jinan University), Jennifer B. Dennison(The University of Texas MD Anderson Cancer Center), Christine B. Peterson(The University of Texas MD Anderson Cancer Center), Sanghee Park(The University of Texas MD Anderson Cancer Center), John W. Davis(The University of Texas MD Anderson Cancer Center), Alia Fleury, Zhe Tang(Second Affiliated Hospital of Zhejiang University), Ehsan Irajizad(The University of Texas MD Anderson Cancer Center)
Cited by 83
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k